These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6218564)

  • 21. Toxicology of cefazolin in animals.
    Birkhead HA; Briggs GB; Saunders LZ
    J Infect Dis; 1973 Oct; 128():Suppl:S379-8. PubMed ID: 4744021
    [No Abstract]   [Full Text] [Related]  

  • 22. Moxalactam--absorption, excretion, distribution, and metabolism.
    Shimada J; Ueda Y
    Rev Infect Dis; 1982; 4 Suppl():S569-80. PubMed ID: 6218568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of cefazolin and moxalactam on serum chemistry values determined by autoanalyzer.
    Polk RE; Stephens GH
    Am J Hosp Pharm; 1981 Jun; 38(6):866-8. PubMed ID: 6454343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers.
    Standiford HC; Drusano GL; McNamee WB; Tatem B; Ryan PA; Schimpff SC
    Rev Infect Dis; 1982; 4 Suppl():S585-94. PubMed ID: 6296967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Toxicological studies of a new cephamycin, MT-141. II. Its subacute toxicity in rats].
    Kurebe M; Yokota M; Yuda Y; Sasaki H; Niizato T; Watanabe H; Hayasaka H
    Jpn J Antibiot; 1984 May; 37(5):855-89. PubMed ID: 6434761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Toxicological studies of a new cephamycin, MT-141. III. Its chronic toxicity in rats].
    Kurebe M; Yokota M; Kawaoto H; Niizato T; Watanabe H; Hayasaka H
    Jpn J Antibiot; 1984 May; 37(5):890-917. PubMed ID: 6434762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity against Bacteroides fragilis.
    Bartlett JG; Joiner KA; Dezfulian M; Marien GJ
    Rev Infect Dis; 1982; 4 Suppl():S664-9. PubMed ID: 6218580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibacterial activity of moxalactam (LY-127935) compared with cefotaxime and other beta-lactam antibiotics against clinical isolates of enterobacteriacea and non-fermenters.
    Verbist L
    Arzneimittelforschung; 1981; 31(6):982-6. PubMed ID: 6266430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefotaxime toxicity studies: a review of preclinical studies and some clinical reports.
    Doerr BI; Glomot R; Kief H; Kramer M; Sakaguchi T
    Rev Infect Dis; 1982; 4 Suppl():S354-9. PubMed ID: 6294784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicology of cefotaxime in comparison to other cephalosporins.
    Doerr BI; Glomot R; Kief H; Kramer M; Sakaguchi T
    J Antimicrob Chemother; 1980 Sep; 6 Suppl A():79-82. PubMed ID: 6252183
    [No Abstract]   [Full Text] [Related]  

  • 31. [Comparative pharmacokinetics of moxalactam and other cephalosporins].
    Fourtillan JB; Brisson AM
    Sem Hop; 1983 Jun; 59(26):1968-71. PubMed ID: 6310788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of the new cephalosporin antibiotics cefotaxime, cefoperazone and lamoxactam].
    Pulverer G; Peters G
    Med Welt; 1982 Apr; 33(17):642-4. PubMed ID: 6285119
    [No Abstract]   [Full Text] [Related]  

  • 33. [In vitro evaluation of moxalactam on enterobacteria producing beta-lactamases].
    Kazmierczak A; Pechinot A; Duez JM; Kohli E; Tremeaux JC
    Sem Hop; 1983 Jun; 59(26):1953-7. PubMed ID: 6310785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute, subchronic, and chronic toxicity studies with 3-O-demethylfortimicin A disulfate, a new aminocyclitol antibiotic.
    Kimura ET; Tekeli S; Pratt MC; Kesterson JW; Cusick PK; Heyman IA; Majors KR
    Toxicol Appl Pharmacol; 1985 Aug; 80(1):66-77. PubMed ID: 4024109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of cefoperazone, moxalactam, cefotaxime, trimethoprim and sulphamethoxazole in experimental meningitis.
    Perfect JR; Durack DT
    J Antimicrob Chemother; 1981 Jul; 8(1):49-58. PubMed ID: 6265429
    [No Abstract]   [Full Text] [Related]  

  • 36. Moxalactam in serious infections: clinical, bacteriologic, and pharmacokinetic studies.
    Giamarellou H; Tsagarakis J; Daikos GK
    Rev Infect Dis; 1982; 4 Suppl():S629-38. PubMed ID: 6218576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative activity of N-formimidoyl thienamycin with third generation cephalosporins and ureido penicillins against multiple resistant Serratia marcescens.
    Miller MA; LeFrock JL; Vercler MJ
    Microbiol Immunol; 1981; 25(11):1119-27. PubMed ID: 6276701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moxalactam therapy vs. standard antimicrobial therapy for selected serious infections.
    Oblinger MJ; Bowers JT; Sande MA; Mandell GL
    Rev Infect Dis; 1982; 4 Suppl():S639-49. PubMed ID: 6218577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.
    Schaad UB; McCracken GH; Loock CA; Thomas ML
    J Infect Dis; 1981 Feb; 143(2):156-63. PubMed ID: 6260870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moxalactam for treatment of nosocomial infections.
    Winston DJ; Kurtz TO; Young LS; Busuttil RW
    Rev Infect Dis; 1982; 4 Suppl():S650-S655. PubMed ID: 6218578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.